A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1

Not Applicable

Not yet recruiting

• Conditions: Progression; Postoperative Recovery
• Interventions: Other: Systemic Lymph Node Dissection; Other: selective lymph node dissection

• Registration Number: NCT05184829
• Lead Sponsor: Shanghai Zhongshan Hospital

Brief Summary

A single-center study on the effect of systemic/selective lymph node dissection on the prognosis of ground glass nodules smaller than 3cm and with components with consolidation/tumor ratio between 0.5-1

Detailed Description

A single-center study on the effect of systemic/selective lymph node dissection on the prognosis of ground glass nodules smaller than 3cm and with components with consolidation/tumor ratio between 0.5-1

Study Timeline

• Status Verified: 2021-12
• Study First Submitted: 2021-12-15
• Study First Submitted QC: 2021-12-28
• Last Update Submitted: 2021-12-28
• Study Start: 2022-01-01
• Study First Posted: 2022-01-11
• Last Update Posted: 2022-01-11
• Primary Completion: 2028-12-31
• Study Completion: 2029-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Patients enrolled in the study must meet all of the following conditions:

• 1.Aged between 25 and 75 years;
• 2. GGO is diagnosed by thin-section lung CT (thickness <1.5mm) within one month before surgery;
• 3. The maximum diameter of the GGO is smaller than 3cm;
• 4. The solid component in GGO between 50%-100%;
• 5. Preoperative examination showed that the patient could tolerate lobectomy;
• 6. The patient is able to understand and comply with the study and has provided written informed consent.

Exclusion Criteria

Patients meeting any of the following criteria are not eligible for this trial:

• 1. Patients with a history of lung surgery;
• 2. Postoperative pathology showed non-primary lung cancer;
• 3. The scope of surgical resection is larger than one lung lobe;
• 4. Patients with a history of other tumors;
• 5. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
• 6. Unable to cooperate with the researchers because of dementia or cognitive decline
• 7. Other situations that are not in conformity with the standards and requirements of this trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
systemic lymph node dissection group	Systemic Lymph Node Dissection	systemic lymph node dissection group
selective lymph node dissection	selective lymph node dissection	selective lymph node dissection

Primary Outcome Measures

Name	Time	Method
Overall survival	From enrollment to 36 months after surgery

Secondary Outcome Measures

Name	Time	Method
Complications	1-2 Weeks after enrollment (after Surgery)	The degrees of cough